Study of B007 for Generalized Myasthenia Gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called B007 for people with generalized myasthenia gravis who have specific antibodies and moderate to severe muscle weakness. It aims to see if the drug can improve daily activities and reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with generalized myasthenia gravis (not the mild eye-only type or very severe crisis)
- Positive for AChR or MUSK antibodies in your blood
- Moderate to severe symptoms: your MG-ADL score (a daily activity rating) is 5 or higher
- On a stable dose of your usual myasthenia gravis treatments (like steroids or immunosuppressants)
- Willing to use effective birth control during the study and for 1 year after the last drug dose (if applicable)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called SHR-2173, given as an injection, for people with generalized myasthenia gravis. It aims to see if the drug can improve muscle strength and daily function.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This study tests a new medicine called HN2301 for people with generalized myasthenia gravis that has not improved with standard treatments. The goal is to see if it is safe and if it helps reduce symptoms.
This trial tests an investigational drug called IMVT-1402 to see if it improves symptoms in people with generalized myasthenia gravis (gMG). If you have mild to severe gMG and are looking for new treatment options, this study may be a fit.
This trial tests a new cell therapy (CAR-T cells) for people with generalized myasthenia gravis. It aims to reduce symptoms and improve daily life by targeting and destroying faulty immune cells.
This trial tests an experimental drug (EA5) injected under the skin or into a vein for people with a specific form of myasthenia gravis (caused by AChR antibodies). The goal is to find the safest dose and see how well it may reduce muscle weakness.
Hear when a new Generalized Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.